Documente Academic
Documente Profesional
Documente Cultură
Etiologie
Sdr Costello
Sdr Noonan
Neurofibromatoza tip 1
Li-Fraumeni
Beckwith-Wiedemann
Complicatii
Neuroblastom stadiul 1
Neuroblastom stadiul 2
În stadiul 2A, tumora se află într-o singura localizare, cu reziduu
postoperator.. Celulele NB nu se găsesc în ganglionii limfatici locali.
Neuroblastom stadiul 3
Neuroblastom stadiul 4
os;
ficat;
piele;
alte organe
Tratament
Carboplatin (paraplatin)
Ciclofosfamidă (Neosar)
Doxorubicină (Adriamycin)
Cei cu risc mare primesc adesea următoarele medicamente:
Busulfan (Busulfex, Myleran)
Carboplatin (paraplatin)
Cisplatin (Platinol)
Ciclofosfamidă (Neosar)
Factori de crestere (GM-CSF și IL2)
Dinutuximab (Quarziba, Unituxin)
Doxorubicină (Adriamycin, Doxil)
Etoposid (VP 16,)
Ifosfamida (Ifex)
Melphalan (Alkeran)
Topotecan
Vincristine (Oncovin)
Radioterapia
Imunoterapia
Prognostic
Prevenție neuroblastom
Referinte:
(1) Neuroblastoma, link: https://www.orpha.net/consor/cgi-
bin/OC_Exp.php?Lng=GB&Expert=635
(2) Neuroblastoma, link: https://www.mayoclinic.org/diseases-
conditions/neuroblastoma/symptoms-causes/syc-20351017
(3) Neuroblastoma, link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668791/
(4) What Is Neuroblastoma?, link:
https://www.cancer.org/cancer/neuroblastoma/about/what-is-
neuroblastoma.html
(5) Neuroblastoma link:https://www.stanfordchildrens. org/en/topic/
default?id= neuroblastoma-90-P02735
Monclair T, Brodeur GM, Ambros PF, et al.: The International
Neuroblastoma Risk Group (INRG) staging system: an INRG
Task Force report. J Clin Oncol 27 (2): 298-303, 2009.
[PUBMED Abstract]
Taggart DR, London WB, Schmidt ML, et al.: Prognostic value of
the stage 4S metastatic pattern and tumor biology in patients
with metastatic neuroblastoma diagnosed between birth and 18
months of age. J Clin Oncol 29 (33): 4358-64, 2011. [PUBMED
Abstract]
Canete A, Gerrard M, Rubie H, et al.: Poor survival for infants
with MYCN-amplified metastatic neuroblastoma despite
intensified treatment: the International Society of Paediatric
Oncology European Neuroblastoma Experience. J Clin Oncol 27
(7): 1014-9, 2009. [PUBMED Abstract]
Pinto NR, Applebaum MA, Volchenboum SL, et al.: Advances in
Risk Classification and Treatment Strategies for Neuroblastoma.
J Clin Oncol 33 (27): 3008-17, 2015. [PUBMED Abstract]
Guglielmi M, De Bernardi B, Rizzo A, et al.: Resection of primary
tumor at diagnosis in stage IV-S neuroblastoma: does it affect
the clinical course? J Clin Oncol 14 (5): 1537-44, 1996.
[PUBMED Abstract]
Katzenstein HM, Bowman LC, Brodeur GM, et al.: Prognostic
significance of age, MYCN oncogene amplification, tumor cell
ploidy, and histology in 110 infants with stage D(S)
neuroblastoma: the pediatric oncology group experience--a
pediatric oncology group study. J Clin Oncol 16 (6): 2007-17,
1998. [PUBMED Abstract]
Nickerson HJ, Matthay KK, Seeger RC, et al.: Favorable biology
and outcome of stage IV-S neuroblastoma with supportive care
or minimal therapy: a Children's Cancer Group study. J Clin
Oncol 18 (3): 477-86, 2000. [PUBMED Abstract]